Skip to main content
. 2015 Aug 11;10(8):e0134648. doi: 10.1371/journal.pone.0134648

Fig 10. Effect of galantamine and/or vildagliptin on insulin signaling pathway.

Fig 10

Effect of different doses of galantamine (Galan 2.5, 5 & 10 mg/kg), vildagliptin (Vilda 3, 10 & 30 mg/kg) and their combination (Galan5 + Vilda 30) on hepatic and muscular contents of phosphorylated insulin receptor (A, B), and p-Akt (C, D), respectively, as well as hepatic GLUT2 (E) and muscular GLUT4 (F) in n-STZ diabetic rats. Drugs were gavaged orally for four weeks. Values are means of 10 rats ± S.E.M as compared with normal control (*), diabetic control (#), Galan5 (η), Galan10 (ɸ) and Vilda30 (Ψ)-treated groups (one-way ANOVA followed by Tukey post hoc test) at P< 0.05. (a) Additive interaction when Galan5 and Vilda30 were combined using Factorial Design.